lundi 15 janvier 2018

Onco Actu du 15 janvier 2018

1. Biologie

How can CRISPR genome editing shape the future of cancer research? [Cancer Research UK]

4.5 Dép., diag. & prono. - Colorectal

How To Tell Grandpa He Is Too Old For Another Colonoscopy [Forbes]

Colonoscopy? How About a Blood Test? [Bloomberg]

5.1 Traitements - Pré-clinique

Decoding cancer-linked enzyme could lead to better EGFR cancer drugs [FierceBiotech]

5.12.1 Immunothérapies - partenariats

Forty Seven lines up Roche as second partner for CD47 cancer immunotherapy [FierceBiotech]

Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven [EndPoints]

5.12.3 Immunothérapies-combinaisons

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field [FiercePharma]

5.2.2 Pharma - Fusions & Acquisitions

Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer [FiercePharma]

5.3.4 Traitements - AMM (FDA, EMA)

Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer [AstraZeneca]

AstraZeneca and Merck score as Lynparza nabs first-ever nod to treat BRCA breast cancer [FiercePharma]

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer [Myriad]

FDA approves first drug aimed at women with inherited breast cancer [STAT]

FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer [Cancer Research Catalyst]

First treatment approved for breast cancer with BRCA genetic mutation [Washington Post]

In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer [EndPoints]

U.S. FDA approves expanded use of AstraZeneca breast cancer drug [Reuters]

FDA approves olaparib for germline BRCA-mutated metastatic breast cancer [FDA]

5.4 Traitements - Economie

At $850,000, price for new childhood blindness gene therapy four times too high, analysis says [STAT]

Non-Profit Says $850,000 Gene Therapy Is At Least Twice As Expensive As It Should Be [Forbes]

Drugmakers see a pricing blueprint in an $850,000 gene therapy [Reuters]

5.5 ASCO

Upcoming Symposium to Feature New Insights for Management of Prostate, Bladder, Kidney Cancers [ASCO]

6.1 Observation

Breast cancer survival not affected by faulty BRCA genes [Cancer Research UK]

Gene Therapy Could Make Cancer Care More Unequal, and This Map Shows Why [MIT Technology Review]

6.7.1 Bioinformatique

Just What The Software Ordered: This AI Could Help Finnish Doctors Spot Cancer [GE]

6.9 Controverses

IARCgate: Shouldn’t IARC Stop Lying? [The Risk-Monger]